Our goal is to understand how cells regulate their growth rates and to relate these processes to our growing knowledge of human cancer progression. Numerous projects in the lab are aimed at understanding these processes and how they might impact tumorigenesis. Members of the lab are translating their findings into clinical settings and potential application through numerous collaborations with School of Medicine physicians.

Pharmacology of Selumetinib for treatment of Neurofibromatosis-1 (New Drug 2020)

MOA – MEK 1/2 or Mitogen Activated Protein Kinase 1/2 inhibitor

Use: Neurofibromatosis-1 which is symptomatic/inoperable

Effect: Selumetinib decreases size and number of neurofibromas.

Route – Oral

Dose – 25 mg/m2 on empty stomach

Side-effects:
GIT – N/V, Diarrhoea
Rhabdomyolysis
Ocular toxicity
Cardiomyopathy

Join the NF Network with John J. Mulvihill, MD, Dept. of Genetics, Oklahoma University Medical Center for an all new webinar on NF1 and aging. Dr. Mulvihill has extensively studied the effects of NF1, aging, and how NF changes during the aging process

Xray lecture on manifestations of neurofibromatosis

Neurofibromatosis type 1 (NF1) is a multisystem genetic disorder that is characterized by cutaneous findings, most notably café-au-lait spots and axillary freckling , by skeletal dysplasias, and by the growth of both benign and malignant nervous system tumors, most notably benign neurofibromas